NASDAQ:RKDA Arcadia Biosciences (RKDA) Stock Price, News & Analysis $0.92 -0.02 (-1.72%) As of 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About Arcadia Biosciences Stock (NASDAQ:RKDA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Arcadia Biosciences alerts:Sign Up Key Stats Today's Range$0.88▼$0.9750-Day Range$0.92▼$2.1652-Week Range$0.88▼$6.71Volume28,570 shsAverage Volume28,848 shsMarket Capitalization$1.89 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Arcadia Biosciences, Inc., founded in 2002 and headquartered in Davis, California, is an agricultural biotechnology company dedicated to developing crops and food ingredients that promote health and sustainability. By harnessing advanced genomics and precision‐breeding technologies, Arcadia creates proprietary trait platforms designed to enhance crop performance, nutritional value, and resilience to environmental stressors. The company’s scientific expertise focuses on non-transgenic approaches, enabling the delivery of novel traits without introducing foreign DNA. Arcadia’s operations span two main segments: Crop Traits and Food Ingredients. The Crop Traits division develops seed traits such as drought tolerance, salt tolerance, and enhanced oil or fiber profiles, which are licensed to major seed companies for integration into commercial seed offerings. The Food Ingredients division leverages specialty crops to produce plant-based ingredients—including high-fiber wheat, functional starches, and plant proteins—targeted at food and beverage manufacturers seeking clean-label, nutritionally improved solutions. To advance its pipeline and broaden its geographic footprint, Arcadia collaborates with global agricultural partners, research institutions, and development agencies. The company conducts field trials and pilot programs across North America, Australia, and Latin America, adapting its trait technologies to diverse agronomic conditions. With a commitment to environmental stewardship, Arcadia aims to reduce inputs such as water and synthetic fertilizers, thereby supporting sustainable agricultural practices. Through strategic alliances and a diversified portfolio, Arcadia Biosciences works to address global food security challenges and meet the growing consumer demand for healthier, more sustainable foods.AI Generated. May Contain Errors. Read More Arcadia Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks9th Percentile Overall ScoreRKDA MarketRank™: Arcadia Biosciences scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingArcadia Biosciences has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageArcadia Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Arcadia Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcadia Biosciences is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcadia Biosciences is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcadia Biosciences has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.34% of the float of Arcadia Biosciences has been sold short.Short Interest Ratio / Days to CoverArcadia Biosciences has a short interest ratio ("days to cover") of 0.16, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Arcadia Biosciences has recently increased by 297.43%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArcadia Biosciences does not currently pay a dividend.Dividend GrowthArcadia Biosciences does not have a long track record of dividend growth. News and Social Media1.3 / 5News Sentiment-1.00 News SentimentArcadia Biosciences has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Arcadia Biosciences this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Arcadia Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Arcadia Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders8.20% of the stock of Arcadia Biosciences is held by insiders.Percentage Held by Institutions17.73% of the stock of Arcadia Biosciences is held by institutions.Read more about Arcadia Biosciences' insider trading history. Receive RKDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcadia Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RKDA Stock News HeadlinesArcadia Biosciences (RKDA) Announces First Quarter 2026 Financial Results and Business HighlightsMay 15, 2026 | markets.businessinsider.comArcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2025 Financial Results and Business HighlightsMarch 26, 2026 | markets.businessinsider.com$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker.May 19 at 1:00 AM | Paradigm Press (Ad)Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2025 Financial Results and Business HighlightsMarch 26, 2026 | globenewswire.comArcadia Biosciences (RKDA) Announces Exercise of Preferred Investment Options for $2.1 Million Gross ProceedsJanuary 12, 2026 | globenewswire.comRKDA stock rises pre-market after company receives merger termination notice from Roosevelt ResourcesDecember 26, 2025 | msn.comArcadia Biosciences stock rises after Roosevelt terminates merger dealDecember 26, 2025 | za.investing.comArcadia Biosciences, Inc. Announces Termination of Securities Exchange Agreement with Roosevelt Resources, LPDecember 26, 2025 | quiverquant.comQSee More Headlines RKDA Stock Analysis - Frequently Asked Questions How have RKDA shares performed this year? Arcadia Biosciences' stock was trading at $1.98 at the beginning of 2026. Since then, RKDA shares have decreased by 53.6% and is now trading at $0.9189. How were Arcadia Biosciences' earnings last quarter? Arcadia Biosciences, Inc. (NASDAQ:RKDA) released its quarterly earnings results on Thursday, May, 14th. The basic materials company reported ($2.11) EPS for the quarter, missing the consensus estimate of ($0.80) by $1.31. The basic materials company earned $1.10 million during the quarter, compared to analysts' expectations of $1.60 million. Arcadia Biosciences had a negative net margin of 195.94% and a negative trailing twelve-month return on equity of 113.73%. When did Arcadia Biosciences' stock split? Shares of Arcadia Biosciences reverse split on Wednesday, January 24th 2018.The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Arcadia Biosciences IPO? Arcadia Biosciences (RKDA) raised $66 million in an IPO on Friday, May 15th 2015. The company issued 8,200,000 shares at a price of $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO. How do I buy shares of Arcadia Biosciences? Shares of RKDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arcadia Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcadia Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), PayPal (PYPL), GE Aerospace (GE), Arista Networks (ANET), Advanced Micro Devices (AMD) and CrowdStrike (CRWD). Company Calendar Last Earnings5/14/2026Today5/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 RKDA's financial health is in the Red zone, according to TradeSmith. RKDA has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryAgriculture Current SymbolNASDAQ:RKDA CIK1469443 Webwww.arcadiabio.com Phone(530) 756-7077Fax530-756-7027Employees60Year Founded2002Profitability EPS (Trailing Twelve Months)($5.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.34 million Net Margins-195.94% Pretax Margin-195.78% Return on Equity-113.73% Return on Assets-68.47% Debt Debt-to-Equity RatioN/A Current Ratio3.79 Quick Ratio3.17 Sales & Book Value Annual Sales$4.86 million Price / Sales0.39 Cash Flow$1.28 per share Price / Cash Flow0.72 Book Value$1.40 per share Price / Book0.66Miscellaneous Outstanding Shares2,060,000Free Float1,888,000Market Cap$1.89 million OptionableNot Optionable Beta0.52 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:RKDA) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcadia Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcadia Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
